

18 November 2014

News Report Misinterprets Substantial Notice

Antisense Therapeutics Limited (ASX:ANP) has become aware of a news report today on nabtrade that has misinterpreted the recent Notice of Change of Interests of Substantial shareholder issued by Circadian Technologies Limited (Circadian) on 17 November 2014 as a result of dilution.

The notice refers to the effect on the Circadian holding as a result of the November 2013 consolidation of shares in ANP on a 1 for 10 basis and the recent capital raising where the holding was consequently diluted from 11.03% to 8.89%.

The news report incorrectly states that Circadian had sold 128,787,604 shares worth \$12,621,185 on November 12, 2014 at 10c per share.

The Company would like to confirm that no shares were sold by Circadian on 12 November 2014. As per the notice, Circadian holds 14,361,583 shares post-consolidation and recent capital raising (8.89%), adjusted and diluted from 143,149,187 (11.03%).

Contact Information:

Website: www.antisense.com.au

Managing Director: Mark Diamond +61 (3) 9827 8999

Australian Investor/Media: Annabel Murphy +61 (0)2 9237 2800; amurphy@buchanwe.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 a second-generation antisense drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.